55.7 F
San Diego
Tuesday, Mar 19, 2024
-Advertisement-

AmpliPhi BioSciences Corp. Names M. Scott Salka as CEO

AmpliPhi BioSciences Corp., which develops antibacterial therapies to treat drug resistant infections, has named M. Scott Salka as the new chief executive officer.

Effective May 18, Salka will replace interim CEO and Chairman Jeremy Curnock Cook, who will remain in his role as chairman.

Since 2010, Salka has served as CEO of Aspyrian Therapeutics Inc., a company focused on developing near-infrared photoimmunotherapy therapies. Prior to this role, he was the CEO of Ambit Biosciences (acquired by Daiichi Sankyo in 2014). During Salka’s tenure at Ambit, a company developing treatments for oncology, autoimmune and inflammatory diseases, he was responsible for transforming the company from a service contract business to a fully capable drug discovery and development enterprise.

Prior to joining Ambit in 2001, he served as the president and CEO of two privately held genomics companies, Arcaris Inc. and 454 Corporation (sold to Roche in 2007). He also previously co-founded one of the first commercial genomics companies, Sequana Therapeutics Inc., a pioneer in the effort to commercialize the international Human Genome Project.

Salka will be based in San Diego in his role as CEO. The company’s headquarters are in Richmond, Va.

AmpliPhi is advancing three pre-clinical programs in methicillin-resistant staphylococcus aureus (MRSA), pseudomonas aeruginosa infections in cystic fibrosis and clostridium difficile.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-